Werewolf Therapeutics Inc (OQ:HOWL)
Business Focus: Biotechnology & Medical Research
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 200 Talcott Avenue, 2Nd Floor WATERTOWN MA 02472 |
| Tel: | N/A |
| Website: | https://werewolftx.com |
| IR: | See website |
| Key People | ||
| Daniel J. Hicklin President, Chief Executive Officer, Director | Timothy W. Trost Chief Financial Officer, Treasurer | Reid J. Leonard Chief Operating Officer |
| Chulani Karunatilake Chief Technology Officer | Randi Isaacs Chief Medical Officer | Ellen A. Lubman Chief Business Officer |
| Business Overview |
| Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712. |
| Financial Overview |
| For the three months ended 31 March 2024, Werewolf Therapeutics Inc revenues decreased 83% to $742K. Net loss increased 35% to $16.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest expense increase from $172K to $1M (expense), Research and Development - Balancing increase of 9% to $7.3M (expense). |
| Employees: | 46 as of Mar 31, 2024 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $119.68M as of Mar 31, 2024 |
| Annual revenue (TTM): | $16.22M as of Mar 31, 2024 |
| EBITDA (TTM): | -$43.64M as of Mar 31, 2024 |
| Net annual income (TTM): | -$41.58M as of Mar 31, 2024 |
| Free cash flow (TTM): | -$38.72M as of Mar 31, 2024 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 43,455,367 as of Apr 29, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.